文献速递中枢神经肿瘤放疗泌尿生殖与妇科肿瘤放疗乳腺癌放疗

青少年和年轻成人(AYA)癌症放疗:利用、结局、晚期毒性与第二原发恶性肿瘤的系统综述

Radiation therapy in adolescents and young adults (AYA): contemporary evidence on utilization, outcomes, late toxicities, and second malignant neoplasms - A comprehensive systematic review and synthesis.
PubMed 文献 · Radiother Oncol · 2026-06-06

现代放疗技术(质子束治疗、VMAT-SIB)在部分瘤种中显示较好的局部控制与早期安全性,但粒子治疗证据在肉瘤和乳腺癌中仍稀缺。模型估计的第二原发恶性肿瘤风险与观察到的潜伏期之间存在差距,需长期登记评估。

要点

  • 中枢神经系统及颅底肿瘤中质子束治疗局部控制率高,但垂体前叶功能障碍发生率36.3%。
  • 睾丸精原细胞瘤质子束治疗显著降低急性胃肠道毒性(1-2级腹泻0% vs 29.5%,p=0.039)。
  • 模型估计质子束治疗使睾丸精原细胞瘤第二原发恶性肿瘤风险降低50-60%。

核心结论

  • 现代放疗技术似乎可减轻AYA最常见研究瘤种的晚期效应负担。
  • 粒子治疗在肉瘤和乳腺癌等临床相关瘤种中的证据仍然稀少。
  • 模型估计风险与观察到的第二原发恶性肿瘤潜伏期之间的差距,需要长期登记评估和标准化器官危及结构剂量学来优化生存者照护。

研究设计与样本

  • 遵循PRISMA 2020报告的系统综述,检索PubMed、Web of Science和Cochrane Library(2026年1月)。
  • 采用无荟萃分析的综合(SWiM)方法进行定性数据综合。

主要发现

  • 中枢神经系统及颅底肿瘤中质子束治疗显示高局部控制率,垂体前叶功能障碍发生率为36.3%。
  • AYA乳腺癌中容积调强弧形治疗同步整合推量(VMAT-SIB)早期安全性良好,中位随访86.5个月未报告心血管事件。
  • 睾丸精原细胞瘤中质子束治疗显著降低急性胃肠道毒性(1-2级腹泻0% vs 29.5%,p=0.039),并与模型估计的第二原发恶性肿瘤风险降低50-60%相关。

关键数值与推荐

  • AYA年龄定义为15-39岁。
  • 垂体前叶功能障碍发生率为36.3%。
  • VMAT-SIB组中位随访86.5个月未报告心血管事件。
  • 质子束治疗组1-2级腹泻发生率为0%,对照组为29.5%(p=0.039)。
  • 质子束治疗与模型估计的第二原发恶性肿瘤风险降低50-60%相关。

临床怎么用

  • 在中枢神经系统及颅底肿瘤AYA患者中,质子束治疗可实现高局部控制,但需关注垂体前叶功能障碍并做解剖学解读。
  • AYA乳腺癌患者采用VMAT-SIB可获得良好的早期安全性,中位随访86.5个月未报告心血管事件。
  • 睾丸精原细胞瘤患者质子束治疗可显著降低急性胃肠道毒性并与模型估计的第二原发恶性肿瘤风险降低相关。
  • 需开展长期登记评估和标准化、部位特异的器官危及结构剂量学,以优化AYA生存者照护。

局限性

  • 粒子治疗在肉瘤和乳腺癌等临床相关瘤种中的证据仍然稀少。
  • 模型估计的第二原发恶性肿瘤风险与观察到的潜伏期之间存在差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adolescent and young adult (AYA; 15-39 years) cancer survivors face decades of potential life-years, making radiotherapy (RT) modality and technique selection central determinants of long-term health. A PRISMA 2020-reported systematic review was performed using PubMed, Web of Science, and the Cochrane Library (January 2026). Data were synthesised qualitatively using a Synthesis Without Meta-analysis (SWiM) approach. The primary synthesis focused on RT utilization and late outcomes including late toxicity, survivorship morbidity, patient-reported outcomes, and secondary malignant neoplasms (SMN), and model-based estimates of SMN risk where available. Thirty-five primary studies were included in the qualitative synthesis. For tumours of the central nervous system (CNS) and skull base, proton beam therapy (PBT) showed high local control; anterior pituitary dysfunction was frequent (36.3 %), requiring anatomical interpretation. In AYA breast cancer, volumetric modulated arc therapy with a simultaneous integrated boost (VMAT-SIB) achieved a favourable early safety profile, with no reported cardiovascular events at a median follow-up of 86.5 months. In testicular seminoma, PBT significantly reduced acute gastrointestinal (GI) toxicity (0 % vs 29.5 % grade 1-2 diarrhoea, p = 0.039) and was associated with a 50-60 % lower model-estimated SMN risk. Modern RT techniques appear to reduce the burden of late effects in AYAs across the most frequently studied tumour sites. However, evidence on particle therapy for clinically relevant tumour sites, including sarcoma and breast cancer, remains scarce. While clinical safety is improving, the disparity between model-estimated risk and observed SMN latency necessitates long-term registry-based evaluation and standardised, site-specific organ-at-risk and substructure dosimetry to refine survivorship care.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Simbirova A, Thomas E, Hessel F, et al. Radiation therapy in adolescents and young adults (AYA): contemporary evidence on utilization, outcomes, late toxicities, and second malignant neoplasms - A comprehensive systematic review and synthesis. Radiother Oncol. 2026. PMID: 42251999. doi:10.1016/j.radonc.2026.111638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。